Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 11: Once-weekly subcutaneous NNC0487-0111 in Chinese adults with overweight or obesity
CTR20263876Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Nov 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing NNC0487-0111 with Placebo (2 arms). Started Nov 2026; status: active.
02
Drugs
amycretin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20263876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263876.